Company Overview and News

 
Rounds Report: Crispr Rallied While FDA Developments Could Benefit Gene-Based Innovators

1h seekingalpha
Shares of Crispr continued to trade further North. The management is gearing up the next growth phase by streamlining its team.
Upvote Downvote

 
Novartis Sees Sharp Decline in Generic Drug Sales During First Quarter

14h biospace
Shares of Novartis are down nearly 3 percent this morning after the company reported a sharp decline in generic drugs and sales results from key branded medicines that missed analysts’ projections for the first quarter.
Upvote Downvote

 
Novartis (NVS) Beats Earnings and Revenue Estimates in Q1

16h zacks
Novartis AG (NVS - Free Report) reported encouraging results for first-quarter 2018 wherein both earnings and revenues beat estimates driven by strong performance of Cosentyx and Entresto.
Upvote Downvote

 
Don’t Leave the Highly Prevalent Chronic Diseases Behind

16h biotech-now.org
There is a lot to be excited about in biotech right now as we are coming off the heels of a near record year for new drug approvals and many exciting, first in class breakthrough products making their way to patients.
Upvote Downvote

6
JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th Position

2018-04-17 seekingalpha
Performance of the Core Biotech Model Account is currently tracking just ahead of the IBB and XBI over the same period of time.
Upvote Downvote

 
Reader Inquiry: Why Is Krystal Biotech Not Participating In The Rally In Gene Therapy Stocks?

2018-04-17 seekingalpha
The gene therapy sector has seen a resurgence after the acquisition of AveXis by Novartis for $8.7 billion.
Upvote Downvote

4
Why 4 Top Biotech Stocks May Be the Next Takeover Targets

2018-04-16 247wallst
Last week, Novartis A.G. (NYSE: NVS) announced a huge $8.7 billion all-cash purchase of AveXis Inc.(NASDAQ: AVXS), and many on Wall Street think there is a good chance that mergers and acquisitions continue in the biotech space. Many of the large companies are flush with cash, and with interest rates still historically low, floating debt to fund purchases still makes sense as well.
Upvote Downvote

 
Geron Corporation: How The Improved Industry Tailwinds Can Help Imetelstat

2018-04-15 seekingalpha
The notorious battleground stock (Geron) is experiencing extreme volatility. Market bulls recently charged ahead but the bears regained some grounds.
Upvote Downvote

1
Portfolio Review: Continued Market Outperformance In Q1 2018

2018-04-15 seekingalpha
Integrated BioSci Investing outperformed all benchmarks since inception as we’ve compounded at the 30% rate. For the same period, the XBI, DOW, and IBB procured 27%, 15%, and 9%, respectively.
Upvote Downvote

1
6 amazing medical advancements to expect in 2018

2018-04-14 cnbc
Things move fast in the world of modern medicine, but if expert predictions about what to expect in 2018 prove true, they might move at a quicker speed than anyone anticipated.
Upvote Downvote

 
Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus

2018-04-13 zacks
The gene therapy space has once again hogged the limelight following the Swiss pharma giant Novartis’ (NVS - Free Report) announcement of the acquisition of AveXis, Inc. (AVXS - Free Report) .
Upvote Downvote

 
Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug

2018-04-13 zacks
Pfizer Inc. (PFE - Free Report) has announced initiation of dosing in a phase Ib study, evaluating its mini-dystrophin gene therapy candidate, PF-06939926, for the treatment of boys aged from five to 12 years with duchenne muscular dystrophy (DMD). Notably, DMD is a genetic disease characterized by muscle degeneration and weakness. The company anticipates initial data from the study in the first half of 2019.
Upvote Downvote

1
Rounds Report: Geron Rallied While FDA's New Guidance Created Tailwinds For Individualized Medicine Innovators

2018-04-13 seekingalpha
Geron Corporation caught a big wave, as the stock rallied robustly in the second half of the trading session. Facing two upcoming binary catalysts (events that can make or break).
Upvote Downvote

 
Sangamo Therapeutics: Deciphering Valuation In The Face Of Key De-Risking Events

2018-04-11 seekingalpha
There's a case to be made for significant undervaluation based on a conservative, albeit simplistic but fitting sum-of-the-parts analysis.
Upvote Downvote

 
Biotech Analysis Central Pharma News: Novartis's Gene Therapy Catch, AstraZeneca's NASH Move, Clovis's Expanded Rubraca Market

2018-04-11 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 84652J103